Centrica Says Trading Conditions Remained Tough In Year To Date

Centrica plc (CNA.L) said that its trading conditions have remained tough in the year to date. However, the modernization of Group remains on track and the difficult, but necessary process to move colleagues onto new terms and conditions is now complete.

The company said that 98% of UK colleagues have accepted the new contracts which will enable the company to better serve the needs of customers.

The factors impacting 2021 outlook remain broadly unchanged since the time of the Preliminary Results in February.

The company continues to expect year-on-year operating cost savings of more than 100 million pounds in 2021.

Centrica noted that the Covid-19 continues to impact the company. In the first-quarter 2021, electricity demand from UK business customers was negatively impacted by around 15%, residential boiler installations were down 11% compared to last year, and non-essential service visits were postponed in order to protect colleagues and customers from the risks of catching and spreading Covid-19.

Bord Gáis Energy's Whitegate power station is now expected to return to service around the end of this year.

The company said it still not provide any specific group earnings or cash flow guidance for 2021.

The company is due to release its 2021 Interim Results on 22 July 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT